Palvella Therapeutics, Inc. Accumulated Other Comprehensive Income
Palvella Therapeutics, Inc. (PVLA) had Accumulated Other Comprehensive Income of $89.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $89.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $95.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $83.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $104.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $89.00K 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $95.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $83.00K 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $104.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$111.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$3.00K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $3.00K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$316.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$436.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$346.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | $28.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | -$339.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$137.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$426.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$254.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $524.00K 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $625.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $953.00K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $829.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $616.00K 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $234.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $194.00K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$295.00K 10-K · filed 2022-03-02 | |
| 2020-09-30 | -$782.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | -$1.06M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$1.23M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$2.00M 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$697.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$2.71M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$2.06M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$2.98M 10-K · filed 2020-03-13 | |
| 2018-09-30 | -$3.05M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$2.57M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$5.97M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$4.70M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$2.49M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | -$2.09M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | -$1.45M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | -$1.50M 10-K · filed 2018-03-15 | -$1.50M 10-K · filed 2017-03-30 |
| 2016-09-30 | -$1.33M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$1.33M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | -$1.43M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | -$1.27M 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$1.15M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | -$1.34M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$1.45M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$843.10K 10-K · filed 2016-03-23 | |
| 2013-12-31 | -$956.27K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |